Drugs Made In America Acquisition II (NASDAQ:DMII – Get Free Report) released its earnings results on Monday. The company reported $0.07 earnings per share for the quarter, FiscalAI reports.
Drugs Made In America Acquisition II Stock Performance
DMII stock remained flat at $10.24 during trading on Monday. The company’s stock had a trading volume of 648 shares, compared to its average volume of 117,942. The company has a 50-day moving average price of $10.19 and a two-hundred day moving average price of $10.08. Drugs Made In America Acquisition II has a 1-year low of $9.86 and a 1-year high of $10.33.
Analyst Ratings Changes
Several research analysts have recently commented on DMII shares. Wall Street Zen raised Drugs Made In America Acquisition II to a “hold” rating in a research note on Saturday, October 24th. Weiss Ratings upgraded Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Drugs Made In America Acquisition II presently has an average rating of “Sell”.
View Our Latest Stock Report on Drugs Made In America Acquisition II
Hedge Funds Weigh In On Drugs Made In America Acquisition II
Hedge funds have recently made changes to their positions in the business. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Drugs Made In America Acquisition II in the 3rd quarter valued at $1,827,000. Periscope Capital Inc. bought a new position in shares of Drugs Made In America Acquisition II during the 3rd quarter valued at about $1,527,000. First Trust Capital Management L.P. bought a new position in shares of Drugs Made In America Acquisition II during the 3rd quarter valued at about $13,218,000. Wealthspring Capital LLC purchased a new position in shares of Drugs Made In America Acquisition II during the third quarter valued at about $4,063,000. Finally, SkyView Investment Advisors LLC purchased a new position in shares of Drugs Made In America Acquisition II during the second quarter valued at about $2,515,000.
About Drugs Made In America Acquisition II
Drugs Made In America Acquisition II is a special purpose acquisition company, or SPAC. It was formed to pursue a merger, acquisition or similar business combination with an operating company. The company has identified the pharmaceutical sector as its area of focus, with an emphasis on businesses connected to the production of drugs in the United States. It does not operate a drug-manufacturing or pharmaceutical business of its own.
Featured Stories
- Five stocks we like better than Drugs Made In America Acquisition II
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Drugs Made In America Acquisition II Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made In America Acquisition II and related companies with MarketBeat.com's FREE daily email newsletter.
